Showing results (181-190 of 211) with videos related to

Sort By:
Pageof 22
Cancer|January 21, 2026
Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter studyAlessandra Iurlo, Daniele Cattaneo, Carmen Fava, et al.
Leukemia Research|April 25, 2016
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasmsLuigi Gugliotta, Alessandra Iurlo, Gabriele Gugliotta, et al.
Cancer|December 28, 2023
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapyFrancesca Palandri, Giuseppe A Palumbo, Giulia Benevolo, et al.
Annals of Hematology|January 3, 2021
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinibGiovanni Caocci, Olga Mulas, Isabella Capodanno, et al.
The Lancet. Haematology|January 21, 2021
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Cancers|October 28, 2023
A Prognostic Model to Predict Ruxolitinib Discontinuation and Death in Patients with MyelofibrosisFrancesca Palandri, Giuseppe A Palumbo, Massimiliano Bonifacio, et al.
American Journal of Hematology|November 14, 2019
Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 casesEmanuela Sant'Antonio, Paola Guglielmelli, Lisa Pieri, et al.
Cancer|December 21, 2019
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosisFrancesca Palandri, Massimo Breccia, Massimiliano Bonifacio, et al.
Cancer|July 30, 2024
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World StudyFrancesca Palandri, Elena M Elli, Erika Morsia, et al.
NEJM Evidence|February 6, 2024
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia VeraTiziano Barbui, Alessandro Maria Vannucchi, Valerio De Stefano, et al.
Pageof 22